Headwind for India’s pharma exports to US

There are between 650 and 670 United States Food and Drug Administration-approved manufacturing plants in India — the highest number outside the United States. Increased tariffs could significantly affect Indian generic drug manufacturers, who typically operate on very thin profit margins. If they're unable to pass these additional costs on to consumers, they may be forced to withdraw from the US market.

by WhatPackaging? Team